Drug Type Radionuclide Drug Conjugates (RDC), Therapeutic radiopharmaceuticals |
Synonyms- |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Differentiated Thyroid Gland Carcinoma | Phase 1 | China | 01 Jan 2026 | |
| HER2 Positive Breast Cancer | Phase 1 | China | 15 Oct 2025 | |
| HR-negative/HER2-low Breast Carcinoma | Phase 1 | China | 15 Oct 2025 | |
| Liver Cancer | Phase 1 | China | 15 Oct 2025 | |
| Metastatic breast cancer | Phase 1 | China | 15 Oct 2025 | |
| Metastatic Soft Tissue Sarcoma | Phase 1 | China | 15 Oct 2025 | |
| Pancreatic Cancer | Phase 1 | China | 15 Oct 2025 | |
| Metastatic Colorectal Carcinoma | Clinical | China | 20 Jun 2025 | |
| Metastatic Digestive System Carcinoma | Clinical | China | 20 Jun 2025 | |
| Neuroendocrine Carcinoma | Clinical | China | 20 Jun 2025 |





